Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Shall We Dance: Evolving Partnerships of Targeted Therapies for AML.

Journal article

Perl AE. and Vyas P., (2022), Clin Cancer Res

Genetic and non-genetic mechanisms of inflammation may promote transformation in leukemia.

Journal article

Vyas P., (2022), Cell Stem Cell, 29, 184 - 186

The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

Conference paper

Sallman D. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S290 - S290

Sowing the seeds of leukemia before birth.

Journal article

Roberts I. and Vyas P., (2021), Science, 373, 155 - 156

A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies.

Conference paper

Lachowiez CA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39

Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay.

Journal article

Juban G. et al, (2021), Haematologica, 106, 1106 - 1119

Load More